TaiGen Biopharmaceuticals Holdings Limited (TPEX:4157)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
13.40
+0.45 (3.47%)
Dec 31, 2025, 2:31 PM CST
18.58%
Market Cap9.54B
Revenue (ttm)38.75M
Net Income (ttm)-184.20M
Shares Out711.83M
EPS (ttm)-0.26
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume7,125,875
Average Volume5,939,368
Open13.00
Previous Close12.95
Day's Range13.00 - 13.75
52-Week Range7.44 - 15.20
Beta0.17
RSI68.56
Earnings DateMar 13, 2026

About TPEX:4157

TaiGen Biopharmaceuticals Holdings Limited, a pharmaceutical company, develops novel therapeutics for transformative diseases worldwide. The company develops Taigexyn (Nemonoxacin), a non-fluorinated quinolone antibiotic for the treatment of bacterial infections. Its product pipeline comprises Taigexyn, which is in phase II clinical trial for the treatment of community-acquired pneumonia/diabetic foot infection; TG-1000, which is in phase III clinical trial to treat influenza A and B, and avian influenza H7N9; Furaprevir, a HCV protease inhibit... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2001
Country Cayman Islands
Stock Exchange Taipei Exchange
Ticker Symbol 4157
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.